New Doses Archives - PharmaLive

Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes

Approvals, Blockbusters, Blood Sugar Levels, Cardiovascular Events, Deaths, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Heart Diseases, New Doses, Stroke, Therapeutics, Type 1 Diabetes

The U.S. Food and Drug Administration approved a 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.

March 28, 2022/by PR Newswire

FDA approves additional doses of Trulicity for type 2 diabetes

Approvals, FDA, FDA/Regulatory, New Doses, Type 2 Diabetes

The U.S. Food and Drug Administration approved two additional doses of Eli Lilly and Company’s Trulicity (dulaglutide).

September 3, 2020/by Andrew Humphreys